Sparfosic acid trisodium is primarily utilized in the field of oncology as an investigational antineoplastic agent. It has been studied for its potential to inhibit the growth of cancer cells, particularly in the context of solid tumors. The compound works by interfering with the synthesis of nucleotides, which are essential building blocks for DNA and RNA, thereby disrupting the proliferation of malignant cells. Its application in clinical trials has focused on evaluating its efficacy and safety in treating various types of cancers, often in combination with other chemotherapeutic agents. Additionally, research has explored its role in enhancing the effectiveness of radiation therapy, making it a promising candidate for multimodal cancer treatment strategies. However, its use requires medical supervision due to potential side effects on the blood and immune systems.